Advances on the role of the deleted in breast cancer (DBC1) in cancer and autoimmune diseases. Issue 2 (26th April 2020)

• Record Type: Journal Article
• Authors: Fang, Qiannan; Bellanti, Joseph A.; Zheng, Song Guo
• Is Part Of: Journal of leukocyte biology. Volume 109:Issue 2(2021)
• Page Start: 449
• Page End: 454
• Publication Date: 2020-04-26
• Subjects: autoimmune diseases -- cancer -- DBC1 -- SIRT1; Leucocytes -- Periodicals; Reticulo-endothelial system -- Periodicals; 571.96
• DOI: 10.1002/JLB.6MR0320-086R
• Languages: English
• ISSNs: 0741-5400

Abstract

Abstract: DBC1 (deleted in breast cancer 1) is a human nuclear protein that modulates the activities of various proteins. Most of the research on DBC1 has focused on metabolism and epigenetics because it is a crucial endogenic inhibitor of deacetylase Sirtuin1 (SIRT1). In this review, we have discussed and summarized the new advances in DBC1 research, mostly focusing on its structure, regulatory function, and significance in cancer and autoimmune diseases. Graphical Abstract: Review summarizes the advance on characterizing DBC1 in disease.